Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $-99,920,000
- P/E (trailing)
- —
- P/E (forward)
- —
- Profit margin
- —
- Debt to equity
- —
Trading
- Volume
- 815
- Avg volume
- 5,100
- Day's range
- $1.97 – $1.97
- Shares out
- —
- Stochastic %K
- 57%
- Beta
- —
- Analysts
- Strong Buy
- Price target
- —
Company profile
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was former...
Show more
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
- Phone
- 514 332 4888
- Website
- https://www.engene.com
- Address
- 4868 Rue Levy, Suite 220, Montreal, Canada
Latest news
No headlines yet.
